Table 5.
Clinical cure definition and outcomes for 24 studies reporting this outcome.
| Study | Clinical cure definition | % Clinical curea | Sig. treatment or pathogen effects |
|---|---|---|---|
| NEGATIVELY CONTROLLED RANDOMIZED CLINICAL TRIALS | |||
| Roberson et al. (39) | Normal milk for 3 d or 2 weeks without recur assessed on d 7 & 36 | 57% Rx1 25% Rx2 53% Rx3 64% Con |
No treatment effect Large pathogen effect |
| Suojala et al. (27) | Absence of signs and normal milk at d2 and/or d21 | Day 2: 8% Rx1 & 20% Con Day 21: 47% Rx2 & 57% Con |
Sig. Treatment effect at d2 but not d21 |
| Schukken et al. (40) | <50% of original case severity score at 7 & 14 d | 54% Rx1 46% Con |
Sig. treatment & pathogen effects |
| Persson et al. (41) | Absence of clinical signs and normal milk on d 3 | 21% Rx1 11% Con |
Not reported |
| Fuenzalida and Ruegg (22) | Return to normal milk for 2 consecutive d within first 10 d after treatment | 86% Rx1 92% Con |
No treatment effects |
| Fuenzalida and Ruegg (25) | Return to normal milk for 2 consecutive d within first 10 d after treatment | 92% Rx1 98% Rx2 90% Con |
No treatment or pathogen effects |
| POSITIVELY CONTROLLED TRIALS - NOT TESTING A NON-INFERIORITY HYPOTHESIS | |||
| Erskine et al. (34) | Additional treatment required within 48 h of initial therapy | 84% Rx1 77%Rx2 |
Sig. treatment effect only for coliform cases |
| Wraight (42) | Normal milk at end of milk withholding | 83% Rx1 81% Rx2 |
No treatment effect Significant effect of pathogen |
| McDougall (43) | Re-treatment within 21 d of enrollment | 16% Rx1 5% Rx2 (% retreated) |
Significant treatment effect |
| Taponen et al. (44) | No systemic or local signs evident by 3–4 weeks post-treatment | 73% Rx1 79% Rx2 |
No treatment effect |
| Sérieys et al. (45) | Return to normal milk & udder at 3, 8, 17, & 22 d | >80% for all groups at all periods | No treatment effect |
| Sérieys et al. (45) | No systemic or local signs evident by 3–4 weeks post-treatment | 75% Rx1 74% Rx2 |
No treatment effect CNS CC higher |
| Swinkels et al. (48) | Severity grade 0 at d 1.5, 5, 14, 21 | 60% Rx1 82% Rx2 |
Significant treatment effect |
| Kalmus et al. (49) | Normal milk and gland by 21 to 28 d | 80% Rx1 75% Rx2 |
No treatment effect |
| Truchetti et al. (50) | Normal milk 21 d after last treatment | 89% Rx1 89% Rx2 |
No treatment effect |
| Cortinhas et al. (51) | Normal Milk & Glands on d 4, 14, and 21 d | 79% Rx1 74% Rx2 |
No treatment effect No pathogen effect |
| Viveros et al. (52) | Absence of signs 4 d after 1st treatment | 95% Rx1 96% Rx2 68% Rx3 58% Rx4 |
Significant effect of Treatment |
| McDougall et al. (53) | Visually abnormal milk at 14 & 21 d | 82% Rx1 81% Rx2 |
No treatment effect |
| POSITIVELY CONTROLLED TRIALS – TESTING A NON-INFERIORITY OR “EQUIVALENCY” HYPOTHESIS | |||
| McDougall et al. (54) | No new treatment within 30 d | 86% Rx1 80% Rx2 84% Rx3 |
Significant effect of treatment |
| McDougall et al. (21) | No re-treatment within 21 d | 72% Rx1 87% Rx2 |
Significant effect of treatment CC sig worse in S. aureus CC sig better in no growth |
| Schukken et al. (55) | Normal milk and gland at 10 and 17 d | 62% Rx1 62% Rx2 |
No significant Rx Effect Significant pathogen effects |
| Vasquez et al. (56) | Normal milk and udder 2 to 5 d | 64% Rx1 68% Rx2 |
No Treatment effect |
| Bryan et al. (57) | Return to normal milk and no further RX up to day 23 | 80% Rx1 80% Rx2 |
No significant treatment or pathogen effects |
| Tomazi et al. (58) | Milk and gland normal 48 h after last treatment | 88% Rx1 94% Rx2 |
No No |
a
Proportions of clinical cure are listed in same order of treatments defined in Table 1.